Furthermore, a phase I/II, prospective, randomized, sham-controlled, double-masked CT (NCT03981549) is ongoing, aiming to determine whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in minimizing or reversing vision loss in eyes with ischemia due to central retinal vein occlusion. The gene discussed is CD34; the disease is ischemia.